Jaime Espín

Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel

Karen Facey, Jaime Espín, E. Kent et al. · PharmacoEconomics · 2021 · 47 citations · Full text

Public Affairs, Health Policy, Pharmaceutical Policy +12

Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework

Aris Angelis, Mark Linch, Gilberto Montibeller et al. · Social Science & Medicine · 2019 · 45 citations · Full text

Business, Decision Sciences, Oncology +13

The impact of biosimilars' entry in the EU market

Joan Rovira, Jaime Espín, Leticia García et al. · 2014 · 42 citations

Public Affairs, Economics, Regulatory Policy +10

Health-related quality of life of X-linked hypophosphatemia in Spain

María I. Luis Yanes, Díaz Curiel M, Pilar Peris et al. · Orphanet Journal of Rare Diseases · 2022 · 42 citations · Full text

Medicine, Child Health, Pediatrics +17

Pharmaceutical Pricing and Reimbursement Information (PPRI) – New PPRI analysis including Spain

Sabine Vogler, Jaime Espín, Claudia Habl · Pharmaceuticals Policy and Law · 2009 · 33 citations

Pharmacy, Pharmaceutical Policy, Pharmacoeconomics +16